Barclays
RDHL

Barclays’s Redhill Biopharma RDHL Stock Holding History

Barclays’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-51
Closed -$5.21K – 4993
2023
Q1 		$5.21K Hold
51
– – ﹤0.01% 4813
2022
Q4 		$7.16K Hold
51
– – ﹤0.01% 4964
2022
Q3 		$26K Hold
51
– – ﹤0.01% 3979
2022
Q2 		$44K Sell
51
-26
-34% -$35.7K ﹤0.01% 4081
2022
Q1 		$193K Hold
77
– – ﹤0.01% 3446
2021
Q4 		$197K Buy
+77
New +$308K ﹤0.01% 3571
2021
Q3 		– Hold
0
– – – 4953
2021
Q2 		– Hold
0
– – – 4832
2021
Q1 		– Hold
0
– – – 4605
2020
Q4 		– Hold
0
– – – 4829
2020
Q2 		– Sell
-11
Closed -$51K – 6123
2020
Q1 		$51K Buy
+11
New +$55K ﹤0.01% 5224

Other funds holding RDHL

CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
MOS
MGO One Seven Beachwood, Ohio $4.98B AUM 22.72% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays's RDHL Position: Q2 2023 in Review

Barclays sold out of Redhill Biopharma (RDHL) in Q2 2023, closing a stake of 51 shares — an estimated $5.21K sold.

Barclays first reported a position in RDHL in Q1 2020 and held it in 7 quarters. The position peaked at $197K in Q4 2021. 18 funds tracked by Wall St. Rank hold RDHL as of Q2 2023.

  • Barclays reported no remaining Redhill Biopharma position as of Q2 2023 after selling out during the quarter.
  • Barclays sold 51 Redhill Biopharma shares in Q2 2023, an estimated $5.21K.
  • Barclays first reported a position in Redhill Biopharma in Q1 2020 and held it in 7 quarters.
  • Barclays's Redhill Biopharma position peaked at $197K in Q4 2021.
  • 18 funds tracked by Wall St. Rank held Redhill Biopharma as of Q2 2023.

Based on Barclays's 13F filing for Q2 2023, filed 3 Aug 2023.